• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

EAN HIGHLIGHTS 2023 – TUESDAY, JULY 4 EDITION

July 4, 2023  

EAN HIGHLIGHTS 2023 – MONDAY, JULY 3 EDITION

July 3, 2023  

Novel approach to MS therapeutics: anti-CD40L

June 21, 2023  

CLINICAL CASES IN MS – A case of worsening mobility during the pandemic

June 13, 2023  

Re-evaluating the balance of efficacy and safety with disease-modifying therapies

June 8, 2023  

Selected highlights from CMSC 2023

June 6, 2023  

NfL – a guide to use in MS practice

May 31, 2023  

AAN update on anti-CD20 agents: long-term data

May 10, 2023  

Emerging role of CHI3L1 as MS biomarker

May 2, 2023  

sNfL a biomarker of future disease activity: APLIOS

April 12, 2023  
Previous
9
10
11
12
13
Next

Browse by Topic

  • MS (444)
  • CLINICAL CASES (22)
  • EAN 2026 (2)
  • AAN 2026 (3)
  • ACTRIMS Forum 2026 (4)
  • EPILEPSY (38)
  • AES 2025 (1)
  • BIOMARKERS IN MS (61)
  • ECTRIMS 2025 (7)
  • Library (18)
  • EAN 2025 (2)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • Ofatumumab 2026 – update on real-world effectiveness posted on September 22, 2026
  • CLINICAL CASES IN NEUROLOGY – A YOUNG WOMAN WITH MILD EARLY MS posted on September 17, 2026
  • Highlights of EAN 2026 – Part 2 posted on July 9, 2026
Copyright 2026 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions